Merrimack Pharmaceuticals (MACK) Shares are Down -4.43%

Merrimack Pharmaceuticals (MACK) : During the past 4 weeks, traders have been relatively bearish on Merrimack Pharmaceuticals (MACK), hence the stock is down -17.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.91% relative to the S&P 500. The 4-week change in the price of the stock is -17.94% and the stock has fallen -4.43% in the past 1 week.

The stock has recorded a 20-day Moving Average of 9.43% and the 50-Day Moving Average is 15.22%.The 200 Day SMA reached 32.45%. Merrimack Pharmaceuticals, Inc. has dropped 35.65% during the last 3-month period . Year-to-Date the stock performance stands at -42.66%.


Merrimack Pharmaceuticals (NASDAQ:MACK): The stock opened in the green at $4.62 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $4.63 and a low of $4.51 for the day. The stock did not find buyers even at the lows and closed at $4.53 recording a loss of -1.31%. 1,255,596 shares exchanged hands during the trading day. The stock had closed at $4.59 in the previous days trading.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.